SRP2084-5UG Display Image

VHL human, recombinant, expressed in insect cells, >=70% (SDS-PAGE)

Code: SRP2084-5UG D2-231

Biochem/physiol Actions

von Hippel-Lindau (VHL) disease is a hereditary cancer with a predilection for the central nervous system and retina. The von Hippel-Lindau tumor supp...


read more

Your Price
£479.00 5UG
£574.80 inc. VAT

Biochem/physiol Actions

von Hippel-Lindau (VHL) disease is a hereditary cancer with a predilection for the central nervous system and retina. The von Hippel-Lindau tumor suppressor gene is mutated in families with von Hippel-Lindau disease and encodes a protein (VHL) of 213 amino acids with an acidic pentapeptide motif in the N-terminus. Mutations in the VHL gene result in constitutive expression of many hypoxia-induced genes, at least in part because of increases in the cellular level of hypoxia-inducible transcription factor HIF-1a. VHL protein binds to elongin B, elongin C, and Cul2 to form a stable complex that targets hypoxia inducible factors (HIFs) for degradation and transcriptional regulation. In addition, VHL protein has also been shown to interact with specific protein kinase C isoforms, histone deacetylases and HIF-1 inhibitor (HIF-1).

Physical form

Clear and colorless frozen liquid solution

Preparation Note

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. While working, please keep sample on ice.

assay≥70% (SDS-PAGE)
biological sourcehuman
colorclear colorless
concentration650 µg/mL
formfrozen liquid
Gene Informationhuman ... VHL(7428)
mol wt~26 kDa
NCBI accession no.NM_000551
packagingpkg of 5 µg
recombinantexpressed in insect cells
shipped indry ice
storage conditionavoid repeated freeze/thaw cycles
storage temp.−70°C
UniProt accession no.P40337
This product has met the following criteria: